- NEWS
Omicron overpowers key COVID antibody treatments in early tests
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
204,58 € per year
only 4,01 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-021-03829-0
References
Cameroni, E. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.12.472269 (2021).
Aggarwal, A. et al. Preprint at medRxiv https://doi.org/10.1101/2021.12.14.21267772 (2021).
Planas, D. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.14.472630 (2021).
Cao, Y. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.07.470392 (2021).
Omicron blindspots: why it’s hard to track coronavirus variants
Omicron is supercharging the COVID vaccine booster debate
Merck’s COVID pill loses its lustre: what that means for the pandemic
COVID antiviral pills: what scientists still want to know